TY - JOUR
T1 - Polymyxin-B immobilized column–direct hemoperfusion for adolescent toxic shock syndrome
AU - Nanishi, Etsuro
AU - Hirata, Yuichirou
AU - Lee, Sooyoung
AU - Kaku, Noriyuki
AU - Momii, Kenta
AU - Kubota, Kensuke
AU - Nishio, Hisanori
AU - Maehara, Yoshihiko
AU - Hara, Toshiro
N1 - Publisher Copyright:
© 2016 Japan Pediatric Society
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Toxic shock syndrome (TSS) is a critical illness associated with toxin from Staphylococcus aureus. Despite recent advances in critical care, mortality remains high and additional effective therapy is required. We report an adolescent case of TSS successfully treated with direct hemoperfusion using polymyxin-B immobilized fiber (PMX-DHP). The patient with spina bifida also had ischial pressure ulcer, and developed TSS associated with methicillin-resistant S. aureus. Despite conventional treatment, the patient developed refractory shock, which was immediately improved with PMX-DHP. PMX-DHP has been widely used for the treatment of sepsis to remove circulating endotoxins produced by Gram-negative bacteria, but beneficial effects have also been reported for Gram-positive bacterial infection. To our knowledge, this is the first report on PMX-DHP for TSS in an adolescent patient, and we propose that PMX-DHP could be a new treatment strategy for severe TSS in children as well.
AB - Toxic shock syndrome (TSS) is a critical illness associated with toxin from Staphylococcus aureus. Despite recent advances in critical care, mortality remains high and additional effective therapy is required. We report an adolescent case of TSS successfully treated with direct hemoperfusion using polymyxin-B immobilized fiber (PMX-DHP). The patient with spina bifida also had ischial pressure ulcer, and developed TSS associated with methicillin-resistant S. aureus. Despite conventional treatment, the patient developed refractory shock, which was immediately improved with PMX-DHP. PMX-DHP has been widely used for the treatment of sepsis to remove circulating endotoxins produced by Gram-negative bacteria, but beneficial effects have also been reported for Gram-positive bacterial infection. To our knowledge, this is the first report on PMX-DHP for TSS in an adolescent patient, and we propose that PMX-DHP could be a new treatment strategy for severe TSS in children as well.
UR - http://www.scopus.com/inward/record.url?scp=84994079362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994079362&partnerID=8YFLogxK
U2 - 10.1111/ped.13087
DO - 10.1111/ped.13087
M3 - Article
C2 - 27804246
AN - SCOPUS:84994079362
SN - 1328-8067
VL - 58
SP - 1051
EP - 1054
JO - Pediatrics International
JF - Pediatrics International
IS - 10
ER -